Good evening :)
$
₹
Moderna Inc

Moderna Inc

MRNA

NASDAQ
Asset Logo

Moderna Inc

MRNA

NASDAQ
$253.062.05% (-5.31)
$
₹
$253.062.05% (-5.31)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $91.2B the stock is ranked 200

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

13.04
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-7.98
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-141.43%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 23 analysts reports

Buy
4 analysts
Hold
16 analysts
Sell
3 analysts

Price Upside

-46.45%

Earnings Growth

-16.83%

Rev. Growth

+8.13%

See Detailed Forecast

Company Profile

Company Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -46.45% growth, versus a trailing 3-year CAGR of 53.05%.

2026
Current$258.38Baseline
Analyst Target - 1 year
Target$138.37-46.45%

All values in $

202220232024202520262027$90.96$155.38$219.80Target-46.45%
2026
Current$258.38Baseline
Analyst Target - 1 year
Target$138.37-46.45%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 8.13% growth, versus a trailing 3-year CAGR of -53.13%.

2025
Current$1.94Baseline
Forecast for Dec 2026
High$2.15+10.83%
Average$2.10+8.13%
Low$1.96+1.01%

All values in $ Billion

20212022202320242025202617.7318.876.843.191.94Low+1.01%Average+8.13%High+10.83%
2025
Current$1.94Baseline
Forecast for Dec 2026
High$2.15+10.83%
Average$2.10+8.13%
Low$1.96+1.01%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-7.27Baseline
Forecast for Dec 2026
High$-7.95-9.35%
Average$-8.49-16.83%
Low$-10.57-45.39%

All values in $

20212022202320242025202628.2919.96-12.41-9.28-7.27Low-45.39%Average-16.83%High-9.35%
2025
Current$-7.27Baseline
Forecast for Dec 2026
High$-7.95-9.35%
Average$-8.49-16.83%
Low$-10.57-45.39%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

1
-0.2
0.6
-0.8
0.3
-1.3
0.1
-0.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.160.221.850.950.100.141.010.670.380.14
Net Income-1.17-1.270.01-1.12-0.97-0.82-0.2-0.82-1.34-0.78
Net Profit Margin-703.59%-578.73%0.70%-117.15%-907.47%-580.98%-19.68%-121.82%-345.24%-539.31%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Moderna Inc -13.040
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare MRNA with any stock or ETF
Compare MRNA with any stock or ETF
Comparing from
MRNA
ABBV
AMGN
Loading...

Frequently asked questions

  1. Moderna Inc (MRNA) share price today is $253.06 as of November 5, 2026 at 8:21 PM IST. The stock touched a day high of $258.54 and a day low of $249.58.

  2. Moderna Inc stock trades on NASDAQ under the ticker symbol MRNA.

  3. Moderna Inc's market capitalization is $91.2B as of November 5, 2026 at 8:21 PM IST.

  4. Moderna Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Moderna Inc's price-to-book (P/B) ratio is 13.04 as of November 5, 2026.

  6. Yes, You can buy Moderna Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Moderna Inc shares in three steps: 1. Search Moderna Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Moderna Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Moderna Inc (MRNA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0395 shares at the current price of $253.06.

Loading...